<DOC>
	<DOCNO>NCT02830542</DOCNO>
	<brief_summary>The study involve administer single dose investigational drug placebo ascend dose cohort . This study design evaluate safety tolerability investigational drug well efficacy investigational drug versus placebo adult primary ( first episode ) Clostridium difficile infection ( CDI ) .</brief_summary>
	<brief_title>SER-262 Versus Placebo Adults With Primary Clostridium Difficile Infection Prevent Recurrence</brief_title>
	<detailed_description>SER-262-001 Phase 1b , randomize , double blind , placebo-controlled , ascend single dose clinical study 2 treatment arm ( SER-262 placebo ) 5 dose cohort . Patients diagnose first ( primary ) episode CDI , define diarrhea ( ≥ 3 unformed stool per day 2 consecutive day ) , positive C. difficile stool test respond standard‑of‑care antibiotic receive investigational drug placebo Day 1 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>1 . Signed informed consent , indicate subject understands purpose procedure require study . 2 . Male female subject ≥ 18 year . 3 . A primary ( first ) episode CDI documentation episode include CDI date , test result , antibiotic treatment ( include start stop date ) , response treatment 1 . Females pregnant , breastfeeding , lactate , plan become pregnant study . 2 . Known suspected toxic megacolon and/or know small bowel ileus . 3 . Active irritable bowel syndrome diarrhea within previous 12 month . 4 . Major gastrointestinal surgery ( eg , significant bowel resection diversion ) within 3 month enrollment ( include appendectomy cholecystectomy ) history total colectomy bariatric surgery . 5 . History inflammatory bowel disease ( ulcerative colitis , Crohn 's disease , microscopic colitis ) diarrhea believe cause active inflammatory bowel disease past 12 month . 6 . Estimated glomerular filtration rate ( eGFR ) &lt; 60 ml/min/1.73m2 7 . Admitted expect admitted intensive care unit medical reason ( board ) . Patients discharge intensive care unit Day 1 may enrol . 8 . Concurrent intensive induction chemotherapy , radiotherapy , biologic treatment active malignancy ( patient maintenance chemotherapy may enrol consultation medical monitor ) . 9 . Absolute neutrophil count &lt; 500 cells/mm3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Clostridium difficile</keyword>
	<keyword>C Diff</keyword>
	<keyword>CDI</keyword>
</DOC>